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Tuberous sclerosis complex (TSC) is a tumor suppres-
sor gene disorder characterized by mutations in the
TSC1 or TSC2 genes. These mutations lead to the
development of benign tumors involving smooth
muscle cells, causing life-threatening lymphangio-
leiomyomatosis. We isolated and characterized two
types of cells bearing a mutation in TSC2 exon 18
from a renal angiomyolipoma of a TSC patient: one
population of -actin-positive smooth muscle-like
cells with loss of heterozygosity for the TSC2 gene (A
cells) and another of nonloss of heterozygosity kera-
tin 8/18-positive epithelial-like cells (R cells). Unlike
control aortic vascular smooth muscle cells, A cells
required epidermal growth factor (EGF) to grow and
substituting EGF with insulin-like growth factor
(IGF)-1 failed to increase the cell number; however,
omission of EGF did not cause cell loss. The A cells
constantly released IGF-1 into the culture medium
and constitutively showed a high degree of S6K phos-
phorylation even when grown in serum-free medium.
Exposure to antibodies against EGF and IGF-1 recep-
tors caused a rapid loss of A cells: 50% by 5 days and
100% by 12 days. Signal transduction mediated by
EGF and IGF-I receptors is therefore involved in A
cell survival. These results may offer a novel thera-
peutic perspective for the treatment of TSC complica-
tions and lymphangioleiomyomatosis. (Am J Pathol
2005, 167:1093–1103)
Tuberous sclerosis complex (TSC) is an autosomal dom-
inant syndrome characterized by the multiorgan devel-
opment of benign and occasionally malignant tumors that
most frequently affect the central nervous system, kidney,
and skin.1 In particular, the kidney tumors include angio-
myolipomas and renal cell carcinomas, of which the
former may cause renal failure as a result of the replace-
ment of kidney parenchyma with tumoral tissue, possibly
leading to life-threatening hemorrhage.2 Angiomyolipo-
mas consist of smooth muscle cells, adipose tissue, and
disorganized thick-walled vascular channels.3
TSC is characterized by mutations in the TSC1 or TSC2
tumor suppressor genes, which seem to act together as
a complex of the encoded hamartin (TSC1) and tuberin
(TSC2) proteins.4 Mutations in TSC1 on chromosome
9q34 and TSC2 on chromosome 16p13 lead to similar
clinical phenotypes, which are more severe in the case of
the TSC2 subtype.5–7 The loss of heterozygosity (LOH)
for the wild-type allele corresponding to the germline
TSC1 or TSC2 mutation in the TSC lesion can be ex-
plained with the two-hit tumor suppressor gene model.8
LOH of both has been documented in angiomyolipomas,
astrocytomas, and rhabdomyomas from TSC patients.9,10
The frequency of LOH varies significantly among tumor
types, being high in angiomyolipomas and low in central
nervous system lesions.9
TSC can occur in association with pulmonary lym-
phangioleiomyomatosis (LAM), a progressive and often
fatal interstitial lung disease characterized by the diffuse
proliferation of abnormal smooth muscle cells and cystic
degeneration of lung parenchyma.11,12 The smooth mus-
cle cells in angiomyolipomas are very similar to those of
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pulmonary LAM, and genetic data suggest that LAM may
be the result of benign cell metastases, a highly unusual
disease mechanism.11 The same mutation and LOH have
been found in the abnormal pulmonary smooth muscle
cells and angiomyolipoma of a large percentage of LAM
patients with renal angiomyolipomas,11,12 which sug-
gests that LAM and TSC may have a common genetic
origin.11,12
The TSC1/TSC2 complex negatively regulate cell size
and proliferation.13,14 TSC2 is a direct target of Akt, a
PI3K-regulated effector that promotes cell growth and
survival by means of a mammalian target of rapamycin
(mTOR)-dependent mechanism.15 Most of the extracel-
lular and intracellular signal pathways involved in the
regulation of growth factor- and nutrient-mediated cell
growth are integrated by mTOR, as is suggested by the
increased phosphorylation of S6 kinase (S6K) and eu-
karyotic initiation factor 4E binding protein-1 (4EBP1).16
Rapamycin is a microbial product that counteracts these
effects by inhibiting mTOR, and Akt is a prosurvival and
pro-oncogenic protein that is phosphorylated after the
activation of growth factor receptors.16 Akt phosphoryla-
tion decreases the ability of TSC2 to inhibit the phosphor-
ylation of the mTOR substrates S6K and 4EBP1,16–18 and
excessive Akt, mTOR, and S6K activation causes various
types of tumor, including hamartomas.1 TSC1 or TSC2
mutant cells show a high degree of S6K and 4EBP1
phosphorylation, but the overexpression of TSC1 and
TSC2 inhibits the phosphorylation of both, thus suggest-
ing that the major cell function of TSC1/TSC2 is to inhibit
translation by blocking the phosphorylation of S6K and
4EBP1.16,19,20
We here describe the isolation and characterization of
two cell populations from an angiomyolipoma of a TSC2
patient: actin-positive smooth muscle-like cells and ker-
atin 8/18-positive epithelial-like cells. We identified the
mutation (corresponding to a TSC2 alteration) that led to
the loss of wild-type alleles in the smooth muscle cell
population. The growth and proliferation of the LOH
smooth muscle-like cells required epidermal growth fac-
tor (EGF) in the culture medium, and the cells released
abundant insulin-like growth factor (IGF)-I into the me-
dium. The addition of IGF-1 to the culture medium stim-
ulated the proliferation of control smooth muscle cells
from human aorta, but not that of the TSC2 LOH smooth
muscle-like cells. Our experiments have been repeated
several times throughout the last 2 years, thus confirming
the reliability of our TSC2 human smooth muscle cells.
Materials and Methods
Establishment of the Angiomyolipoma Culture
The spontaneous renal angiomyolipoma sample (30 cm)
was obtained during total nephrectomy from a 42-year-
old female with a history of TSC who had given her
informed consent according to the Declaration of Hel-
sinki. The study was approved by the Institutional Review
Board of Milan’s San Paolo Hospital.
The tumor tissue was dissociated using sterile filtered
collagenase type II (Sigma, St. Louis, MO) in phosphate-
buffered saline after manual dissociation by means of
repetitive pipetting. The collagenase was neutralized with
a serum-containing medium (50/50 mixture of Dulbecco’s
modified Eagle’s medium/Ham F12; Euroclone, Paignton,
UK) supplemented with hydrocortisone 2  107 mol/L
(Sigma), EGF 10 ng/ml (Sigma), sodium selenite 5 
108 mol/L (Sigma), insulin 25 g/ml (Sigma), transferrin
10 g/ml (Sigma), ferrous sulfate 1.6  106 mol/L
(Sigma), and 15% fetal bovine serum (Euroclone) as
indicated by Arbiser and colleagues.21 The CT/G human
aorta vascular smooth muscle cells (VSMCs) were main-
tained in F12 medium containing 10% fetal bovine serum
(American Type Culture Collection, Manassas, VA).
Histology and Immunohistochemistry
The tissue was frozen in liquid nitrogen-cooled isopen-
tane, and stored at 80°C until sectioning. The angio-
myolipoma was routinely stained with hematoxylin and
eosin (H&E). The slides were deparaffinized and rehy-
drated in graded concentrations of ethanol to distilled
water. Endogenous peroxide activity was blocked with
3% hydrogen peroxide for 30 minutes at room tempera-
ture, followed by a brief rinse in distilled water and a wash
in phosphate-buffered saline. The tissue sections under-
went pepsin enzyme digestion before antibody staining.
Nonspecific background noise was inhibited by means of
incubation in 5% goat serum. The primary -actin HHF-35
(1:100; DAKO, Carpinteria, CA), HMB45 (1:100, DAKO),
and RhoA antibodies (1:100; Santa Cruz Biotechnology,
Santa Cruz, CA) were incubated overnight at 4°C, and
localized using the avidin-biotin complex immunoperox-
idase method with the immunopure standard ABC stain-
ing (Pierce, Rockford, IL) diluted 1:100.
Cell Immunofluorescence Microscopy
The cells were cultured on glass slides, permeabilized with
70% methanol for 10 minutes, and dried in air. The primary
antibodies against -actin (1:100; Sigma), vimentin (1:70;
Santa Cruz), HMB45 (1:100; DAKO), S100 (1:8000; DAKO),
CD68 (1:100, DAKO), keratin 8/18 (1:100, Santa Cruz),
hamartin (1:100, a gift from Dr. Nellist and Dr. Halley, Eras-
mus University, Rotterdam, The Netherlands), and RhoA
(1:100; Santa Cruz) were applied overnight at 4°C. The
samples were incubated for 3 hours at room temperature
with fluorescein isothiocyanate-conjugated rabbit anti-
mouse antibody (Chemicon, Temecula, CA) for -actin,
HMB45, CD68, and keratin 8/18, and fluorescein isothiocya-
nate-conjugated donkey anti-goat antibody (Chemicon) for
vimentin and S100, and rhodamine-conjugated goat anti-
rabbit antibody (Chemicon) for hamartin and RhoA. After
washing, the slides were mounted in 50% glycerol with 1
g/ml 4,6-diamidino-2-phenylindole.
Mutation Study
The DNAs were extracted from peripheral lymphocytes
and cultured cells using the Wizard Genomic DNA puri-
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fication kit (Promega, Madison, WI). All of the exons of
TSC1 and TSC2 from the genomic DNAs were amplified
by means of standard polymerase chain reaction (PCR)
and previously described primers22 in a 25-l final vol-
ume mix containing 10 to 50 ng of genomic DNA, 200
mol/L dNTPs, 1.5 mmol/L MgCl2, 10 pmol of each
primer, and 1.25 U of AmpliTaq Gold (Applied Biosys-
tems, Foster City, CA). The TSC1 and TSC2 amplimers
were divided into those that were successfully amplified
at annealing temperatures of, respectively, 55°C, 60°C,
and 65°C. Mutations were detected by submitting the
PCR products to denaturing high-performance liquid
chromatography (DHPLC) (Transgenomic, Crewe, UK).
To enhance heteroduplex formation, the untreated PCR
product was denaturated at 94°C for 5 minutes followed
by gradual reannealing at 35°C for 1 hour. The samples
were analyzed at the melt temperature determined using
the DHPLC melt software. The products showing variant
DHPLC melt profiles were directly sequenced using a
BigDye terminator cycle sequencing kit (Applied Biosys-
tems), and the results were analyzed using sequence
analysis 3.4.1 software (Applied Biosystem). The se-
quencing reactions in which mutations were identified
were repeated at least twice.
LOH Analysis
The panel of microsatellite markers near the TSC2 locus
on chromosome 16p13.3 consisted of Kg8, D16S287,
D16S291, D16S525, D16S665, D16S3024, and
D16S3394. The sense primers were labeled with 6-FAM
fluorescent dyes (M-Medical, Cornaredo, Italy). The
primer sequences were obtained from the Genome Da-
tabase (www.gdb.org). LOH was analyzed in a 25-l final
volume mix containing 10 to 50 ng of genomic DNA, 200
mol/L dNTPs, 1.5 mmol/L MgCl2, 10 pmol of each
primer, and 1.25 U of AmpliTaq Gold (Applied Biosys-
tem). PCR amplification consisted of 94°C for 10 minutes
followed by 32 cycles of 94°C for 1 minute, 60°C for 1
minute, 72°C for 1 minute, and final extension at 72°C for
15 minutes. The PCR products were analyzed using a
310 ABI prism (Applied Biosystems). All of the analyses
were repeated at least twice.
Western Blotting
The tissues were homogenized using an Ultra Turrax
polytron in 5 vol of a homogenization buffer consisting of
25 mmol/L Tris-HCl, pH 7.4, 0.4 mmol/L sodium azide, 0.4
mmol/L phenylmethyl sulfonyl fluoride, 1 mmol/L benza-
midine-HCl, 0.4 EDTA, 0.4 mmol/L EGTA, and 0.25 mol/L
sucrose. The homogenate was centrifuged at 1500  g
for 10 minutes at 4°C, and the supernatant was used for
Western blot analysis. The cells were lysed in lysis buffer
(5 mmol/L EDTA, 100 mmol/L deoxycholic acid, 3% so-
dium dodecyl sulfate). The tissue and cell samples (50
g) were boiled, electrophoretically run on a 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis gel,
and transferred to nitrocellulose membranes (Amersham,
Arlington Heights, IL). After being blocked at room tem-
perature for 3 hours with 5% dry milk (Merck, Darmstadt,
Germany), the membranes were incubated overnight at
4°C with antibodies against tuberin (1:1000; Cell Signal-
ing, Beverly, MA) and tuberin (C-20) (1:100; Santa Cruz),
phospho-tuberin (1:1000; Cell Signaling), hamartin, the 
subunit of the IGF-1 receptor (1:100; Santa Cruz), EGF
receptor (1:200; Santa Cruz), phospho-Akt (1:500; Pro-
mega), Akt (1:200; Santa Cruz), phospho-S6K (1:1000;
Cell Signaling), S6K1 (1:1000; Cell Signaling), phos-
pho-S6 ribosomal protein (Ser235/236) (1:1000; Cell Sig-
naling), phospho-4EBP1 (1:1000; Cell Signaling), 4EBP1
(1:1000; Cell Signaling), phospho-extracellular signal-
regulated kinase (ERK) (1:1000; Cell Signaling), and
phospho-mTOR (1:1000; Cell Signaling). The mem-
branes were washed and incubated for 1 hour with anti-
mouse antibody (1:10,000; Chemicon) for phospho-S6K
and anti-rabbit antibody (1:10,000; Chemicon) for all of
the other antibodies. The reaction was revealed using the
SuperSignal West Pico chemiluminescent substrate
(Pierce).
Evaluation of Cell Growth and Proliferation
The growth rates of the smooth muscle-like and epithelial-
like cells were compared by counting at least 400 to 500
cells in an improved Neubauer chamber after 4 and 8
days of culture. The proliferation growth factor depen-
dence of the smooth muscle-like cells and VSMCs were
assayed in the presence or absence of EGF (10 ng/ml) or
by replacing EGF with IGF-1 (50 and 5 ng/ml), by count-
ing the cells after 4, 7, 10, 15, and 21 days of culture in
the Neubauer chamber. The action of rapamycin was
evaluated by adding 1 ng/ml to the A cells at plating
time, with or without EGF, and measuring cell proliferation
after 3, 5, and 10 days. Anti-EGF receptor (clone 225;
Calbiochem, Darmstadt, Germany), anti-EGF receptor
(clone EGFR.1; Calbiochem), and anti-IGF-1 receptor
(clone IR3; Calbiochem) were added at a concentration
of 5 g/ml to the complete medium and to the medium
deprived of EGF, and cell proliferation was evaluated
after 2, 5, 10, and 12 days of culture. The action of
wortmannin (Sigma) and PD98059 (Sigma) was evalu-
ated by adding them to the culture medium, and evalu-
ating their effect on cell proliferation 48 hours later. Each
data point of the proliferation experiments is the mean of
four independent experiments.
IGF-1 Enzyme-Linked Immunosorbent Assay
The IGF-1 released by the A cells was assayed using an
IGF-1 enzyme-linked immunosorbent assay kit in accor-
dance with the manufacturer’s instructions (KAPB2010;
Biosource Europe S.A., Nivelles, Belgium). The cells were
incubated for 24 hours before the medium was collected
and IGF-1 determined. These assays were performed 14
and 21 days after A plating.
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Statistical Analysis
The data are expressed as mean values  SEM, and
were statistically analyzed using Student’s t-test; signifi-
cance is indicated for P values of *0.05 and *** 0.001.
Results
Angiomyolipoma Immunohistochemical Staining
The H&E-stained sections of the angiomyolipoma (the
source of the isolated cells, see below) contained three
typical histological components: adipocytes, smooth
muscle cells, and vascular structures (Figure 1a). The
cells positive for -actin were mainly present in the vessel
walls and related surroundings (Figure 1b); the HMB-45-
labeled cells23,24 were located in the outermost layer of
blood vessels and throughout the angiomyolipoma (Fig-
ure 1c). The immunohistochemical evaluation of RhoA, a
small GTPase that promotes the formation of stress fi-
bers) showed several positively stained cells in the an-
giomyolipoma (Figure 1d). The activation of RhoA, Rac,
and Cdc42 is critical for cell adhesion and motility, and
their dysregulation induces cell transformation and
metastasis.25
Cellular Characterization
Two cell populations were isolated from the angiomyoli-
poma and cultured in monolayers before being sepa-
rated by sequential subcloning to obtain pure homoge-
neous cultures. Routine H&E staining (Figure 2A) showed
that one population had a characteristic flat and elon-
gated appearance (Figure 2A; a to c) and the other had
an epithelial-like morphology (Figure 2d). The growth of
the flat and elongated cells was much faster than that of
the epithelial-like cells (Figure 2B): from a plating density
of 3  104 cells, they quadrupled to 12  104 in 8 days.
All of these cells were strongly positive for smooth mus-
cle-specific -actin antibody (Figure 3a), with the stain
being diffused throughout the cytoplasm, and are prob-
ably smooth muscle cells. They were also positive for
HMB-45 antibody (Figure 3e), which is consistent with the
previously described angiomyolipoma phenotype. Be-
cause they were negative for S100 (Figure 3b), vimentin
Figure 1. a: Histological and immunohistochemical staining with -actin-,
HMB-45-, and RhoA-specific antibodies on adjacent sections of an angio-
myolipoma in a TSC patient. H&E staining. b: Immunolabeling with -actin
antibody shows positive cells surrounding a blood vessel and others spread
in the parenchyma. c: The HMB-45-labeled cells distributed in the periphery
of a blood vessel and in the surrounding parenchyma. d: The RhoA-positive
cells were small and distributed throughout the angiomyolipoma but away
from blood vessels (arrows). Original magnifications: 100 (a); 200
(b–d).
Figure 2. Morphological appearance and growth rate of the two cell types
isolated from the TSC human angiomyolipoma. A: H&E staining of flat-
elongated smooth muscle-like cells at different magnifications (a, b) and at
confluence (c), and rounder epithelial-like cells (d). B: Growth rate of
smooth muscle-like and epithelial-like cells 4 and 8 days after plating. *P 
0.05 and ***P  0.001 indicate significant differences versus smooth muscle-
like cell proliferation. Scale bars: 40 m (a, d); 20 m (b, c).
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(Figure 3c), keratin 8/18 (Figure 3d), and CD68 (Figure
3f), they were christened A because of their -actin
antibody reactivity. On the contrary, the epithelial-like
cells strongly reacted with keratin 8/18 antibody (Figure
3d’) and with HMB45 (Figure 3e’), but were negative for
-actin (Figure 3a’), S100 (Figure 3b’), vimentin (Figure
3c’), and CD68 (Figure 3f’).
Hamartin and tuberin regulate the RhoA promoter of
stress fiber formation, and the absence of the TSC1/TSC2
complex leads to stress fiber disassembly and focal ad-
hesion remodeling, thus deregulating cell dynamics.26,27
Because the epithelial-like cells were strongly stained by
RhoA, they were christened R cells (Figure 3, h and h’).
Both cell types were positive for the TSC1 gene product,
hamartin, which was localized in the cell cytoplasm (Fig-
ure 3, g and g’).
Mutation Analysis
DNA sequencing has shown that blood, angiomyoli-
poma, and smooth muscle-like cells contained a germ-
line TSC2 exon 18 mutation consisting of a base pair
change in amino acid 698 from a lysine to a stop codon
(K698X). This mutation inhibits tuberin tyrosine phos-
phorylation and the formation of the tuberin-hamartin
complex.28 K698X-mutated tuberin should be unable
to inhibit S6 kinase16 or interact with 14-3-3.29 This
mutation was also heterozygously present in peripheral
blood and the epithelial-like R cells. Sequencing of
the A cells exclusively revealed mutant residue T at
position 2110, thus indicating LOH of the TSC2 allele
containing wild-type residue A (Figure 4A). The muta-
tion detected in one copy in the A cells was consis-
Figure 3. The two cell types isolated from the TSC angiomyolipoma were exposed to several antibodies to reveal their immunocytochemical characteristics.
Exposure to -actin antibody (a and a’) specific for smooth muscle cells showed that all of the flat-elongated smooth muscle-like cells were positive and the
epithelial-like cells were negative; both cell types were negative for S100, a marker of lipid-containing cells (b and b’), vimentin, a marker of fibroblasts (c and
c’), and CD68, a marker of macrophages, monocytes, neutrophils, basophils, and large lymphocytes (f and f’); keratin 8/18 (d and d’), and RhoA (h and h’)
antibodies labeled the epithelial-like cells; the smooth muscle-like cells were negative for keratin 8/18 and slightly positive for RhoA. Both cell types were
positively marked by antibodies to HMB-45 (e and e’) and hamartin (g and g’).
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tent with Knudson’s two-hit tumor-suppressor gene
model.30
LOH Analysis
We tested the blood and A and R cells of the TSC
patient for LOH by means of PCR amplification using a
panel of microsatellite markers near the TSC2 locus
on chromosome 16p13.3. Five markers (D16S287,
D16S291, D16S525, D16S665, and Kg8) were heterozy-
gous in all of the samples (data not shown), but two
(D16S3024 and D16S3394) showed LOH in the A cells
but not in the blood and R cells (Figure 4, B and C).
Tuberin and Hamartin Expression
The 180-kd tuberin protein is expressed in many different
cell and tissue types,31 and we evaluated the expression
of the TSC complex in LOH A cells, patient specimens,
R cells, and VSMCs. The use of two antibodies recog-
nizing different regions of tuberin in the catalytic domain
showed that tuberin was expressed in the liver, angio-
myolipoma, VSMCs, and R cells, but not in the A cells,
thus confirming the results of the LOH analysis (Figure 5).
In response to PI3K activation, tuberin is directly phos-
phorylated by Akt at Thr1462 and Ser939, and a tuberin
lacking PI3K-dependent phosphorylation sites can block
the activation of S6K1.18 High levels of Thr1462-phos-
phorylated tuberin were detected in the liver and angio-
myolipoma of the TSC2 patient, but they were low in the
R and VSMCs, and absent in the A cells (Figure 5).
Hamartin expression was comparable in all of the tested
groups (Figure 5).
Role of EGF and IGF-1 on A Cell Growth and
Survival
The A cells were isolated and cultured in a medium
containing EGF at a concentration of 10 ng/ml, as indi-
cated by Arbiser and colleagues.21 EGF and IGF-1 re-
ceptors were detected in the A cells, the liver, and AML
of the TSC2 patient, and the VSMCs (Figure 6A). The role
of EGF and IGF-1 in A cell growth was evaluated by
eliminating EGF from the culture medium or replacing
EGF with IGF-1 at concentrations of 5 or 50 ng/ml for 21
days. Under all conditions, the A cells survived but did
not proliferate when EGF was removed from the medium
or reduced to 1 ng/ml (these latter data are not shown),
and so IGF-1 did not replace its proliferative action (Fig-
ure 6B). The opposite effect was observed in the VMSCs:
their number markedly increased when IGF-1 was added
to the culture medium, but their proliferation was quickly
blocked by EGF supplementation (Figure 6C). The early
slight effect of EGF on VSMC proliferation may be sec-
ondary to the reported brisk DNA synthesis with minimal
cell division throughout 0 to 4 days that subsequently
leads to cycle arrest.32 When rapamycin was added to
the culture medium of A cells at plating time, their
growth rate was comparable with that of the VSMCs, and
the action of rapamycin was not modified by the pres-
ence or absence of EGF (Table 1).
Depriving the medium of EGF for 21 days or replacing
it with IGF-1 increased the phosphorylation of Akt in the
A cells, but did not modify its expression, the phosphor-
Figure 4. A: Determination of bi-allelic inactivation by direct sequence
analysis of blood, R cells, and A cells. The mutation site is indicated by a
vertical arrow. A cell sequencing revealed the mutation in TSC2 exon 18
at residue 2110. Representative PCR analysis of chromosome 16p13.3 mic-
rosatellite markers D16S3024 (B) and D16S3394 (C) in blood, R cells, and
A cells.
Figure 5. Expression of the TSC1/TSC2 complex in the liver and angiomyo-
lipoma of the TSC2 patient and in A and VSMCs. Western blots were made
using two antibodies recognizing different regions of the COOH-terminal
domain (tuberin and tuberin C20), an antibody reacting with the Thr1462-
phosphorylated tuberin form, and another for hamartin. The blots are rep-
resentative of three separate experiments.
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ylation and expression of S6K1 and the phosphorylation
of its substrate ribosomal protein S6, or the phosphory-
lation of ERK (Figure 7A). When the A cells were ex-
posed to serum-deprived medium for 24 hours, phospho-
S6K1 expression was not modified (Figure 7B), and
incubation with IGF-1 for 2 hours did not modify that of
phospho-Erk (Figure 7C). The phosphorylation of 4EBP1
decreased when EGF was not added to the medium,
even when IGF-1 was supplemented, its expression did
not change under any of the culture conditions. The
omission of EGF from the culture medium increased
phosphorylated mTOR in comparison with the levels ob-
served in the cells grown in complete medium; this was
not affected by IGF-1 (Figure 7A). The addition of PI3K
(wortmannin) or MAPK inhibitors (PD98059) to the stan-
dard medium did not influence the A cell growth rate:
after 48 hours of exposure the A cells increased from
36  104 to 57.2  104 cells in standard medium, to
54.3 104 cells with 40 nmol/L wortmannin, to 53.2 104
cells with 320 nmol/L wortmannin, and to 54.4 104 cells
with 30 mol/L PD98059. Their average 24-hour IGF-1
secretion after 14 and 21 days in culture was respectively
9.10 0.21 ng/1.5 105 cells and 14.21 0.65 ng/1.5
105 cells.
Antibodies raised against the EGF receptor (EGFR)
and directed to the ligand binding site (clone 225) or the
cell surface domain (clone EGFR.1), and antibody
against the IGF-1 receptor (IGF-1R) were added to the
A cell culture medium with EGF (Figure 8A) and without
EGF (Figure 8B), and the evaluation of cell proliferation
showed that, in both cases, antibody exposure led to a
rapid decrease in cell number that reached 50% in 5
days when anti-IGF-1R and anti-EGFR clone EGFR.1
were used. It seems that both of these antibodies may be
slightly more effective than anti-EGFR clone 225 (P 
0.05). Total cell loss was reached within 12 days of anti-
body exposure. These data suggest that IGF-1 is re-
leased autocrinally and may act on A cell survival,
whereas EGF may act on both proliferation and survival.
These cells do not release EGF (data not shown).
Discussion
TSC is a tumor suppressor gene disorder associated with
benign and malignant tumors. Lesions such as cortical
tubers, subependymal giant cell astrocytomas, cardiac
rhabdomyomas, and renal angiomyolipoma often show
abnormal differentiation patterns, as well as deregulated
cell growth and proliferation.1,14,15 Angiomyolipomas are
uncommon renal tumors that have smooth muscle, fat,
and vascular components, and belong to a group of
neoplasms that co-express melanocytic and smooth
muscle markers, including LAM of the lung.8
The TSC2 gene product, tuberin, functions as a renal
tumor suppressor and regulates cell growth and cell
cycle progression, and its loss may lead to abnormal cell
proliferation.13 LOH of TSC2 mutations occurs in 60% of
the angiomyolipomas taken from women with the spo-
radic form of LAM, specifically in smooth muscle cells
and fat components.12 Cultured cells from human TSC2
angiomyolipomas may be an optimal means of studying
and developing appropriate pharmacological strategies
aimed at blocking the life-threatening growth of smooth
muscle cells in TSC and LAM. The advantages of using
Table 1. Cell Growth Rate
Days 3 5 10
VSMC 35% 60% 107%
A cells with RAPA and EGF 25% 35% 100%
A cells with RAPA, without EGF 24% 36% 100%
A cells in standard medium 36% 68% 240%
Percentage increase in cell number. Rapamycin (RAPA) at the
concentration of 1 ng/ml was added at plating time. At time 0 cells
(50  104 cells) were plated and the number of cells was evaluated at
the indicated time.
Figure 6. Evaluation of the role of EGF and IGF-1 on A cell growth. The cells
were counted in a Neubauer chamber after 4, 7, 10, 15, and 21 days of culture.
A: Expression of EGF receptor (EGFR) and IGF-1 receptor (IGF-1R) in the liver
and angiomyolipoma of the TSC2 patient, and in A and VSMC cells. B: A cell
growth in complete medium (containing 10 ng/ml EGF), in the same medium
without EGF, and without EGF with the addition of IGF-1 50 or 5 ng/ml. The A
cells proliferated and significantly increased in number only in the presence of
EGF; IGF-1 failed to promote any increase. No reduction or mortality was
observed under any of the experimental conditions. C: VSMC proliferation in
specific standard medium, in the presence of 10 ng/ml EGF, and in the presence
of 50 ng/ml IGF-1. IGF-1 supplementation led to a significant increase in cell
number. Mean values  SEM. Significant differences (*P  0.05, ***P  0.001)
versus control were evaluated by Student’s t-test.
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human pathological TSC2 cells rather than knockout
models are obvious and our results highlight some of
them.
We here report the novel finding that the in vitro growth
of smooth muscle-like cells derived from the renal angio-
myolipoma of a TSC2 patient depends on the availability
of EGF in the medium. Both the blood and angiomyoli-
poma cells showed a somatic TSC2 gene mutation in
exon 18 consisting of a stop codon. The same gene
modification was also present in isolated cells. To the
best of our knowledge, only one previous study has
shown that angiomyolipoma cells with TSC2 mutations
can be grown in culture, although the number of such
studies may have been limited by the loss of the entire
primary culture.33
Our isolated angiomyolipoma cells can be grown in
culture as a stabilized cell line, and so could be used as
a continuous source and do not require any morpholog-
ical, biochemical, and pharmacological modifications
(see summary of A and R cell characterization in Table
2). They have been stored in liquid nitrogen and grown in
culture for the past 2 years without any changes in their
growth, pharmacological, or genetic characteristics. The
subcloned smooth muscle cells (A) are LOH and do not
express tuberin, whereas the 8/18 keratin-positive cells
are non-LOH and contain tuberin and its phosphorylated
form. Other angiomyolipoma cell cultures have been re-
cently reported, but the cells did not carry TSC1 or TSC2
mutations, and immortalization required the introduction
of simian virus 40 large T antigen and telomerase.21
EGF transiently activates Erk, a member of the MAPK
family. EGF supplementation of the culture medium is
necessary to promote the proliferation and maintenance
of the A cells, and its proliferative action cannot be
replaced by the addition of IGF-1. Conversely, the prolif-
eration rate of our control aorta smooth muscle cells
(VSMCs) increased when IGF-1 was added to the growth
medium and did not proliferate when exposed to EGF,
thus demonstrating a clear difference between normal
smooth muscle cells and our TSC2-deficient cells. The
EGF-dependent growth is probably tuberin-dependent
because blocking mTOR with rapamycin led to an A cell
growth rate that was comparable with that of the VSMCs.
It therefore seems that the EGF-dependent growth is
triggered by mTOR activation. The requirement of EGF
supplementation for A cell proliferation and the effect of
anti-EGF-R antibodies on A cell survival suggest a pos-
sible new therapeutic strategy for controlling smooth
muscle cell growth in angiomyolipomas and LAM.
Akt is activated in response to insulin or IGF-1 receptor
activation, and is thus capable of phosphorylating tu-
Figure 7.Western blot evaluation of the expression of Akt and its phosphorylated form on Ser473, S6K1, and its phosphorylated form on Thr389, 4EBP1, and
its phosphorylated form on Thr37/46, the phosphorylated form of ERK on Thr202/Tyr204, and Ser2448-phosphorylated mTOR. A: The A cells were cultured for
21 days in standard medium, and in the same medium without EGF in the absence or presence of IGF-1 (50 ng/ml). The A cells were grown for 24 hours in
serum-free medium without EGF and IGF-1 before S6K1 phosphorylation was evaluated (B), and incubated for 2 hours with IGF-1 before phospho-Erk was
evaluated (C). The blots are representative of three experiments.
Figure 8. Effect of antibodies (5 g/ml) to EGF and IGF-1 receptors on A
cell number. A total of 5  104 cells were plated and the antibodies were
added to the complete medium (A) or to the same medium without EGF (B);
the cells were then counted in a modified Neubauer chamber. There was a
50% reduction in cell number within 5 days, and complete cell loss in 12
days. Anti-IGF-1R and anti-EGFR clone EGFR.1 were apparently more effec-
tive than anti-EGFR clone 225, the difference being significant (P  0.05) 5
days after plating. Mean values  SEM. Significant differences (*P  0.05,
***P  0.001) versus control were evaluated by Student’s t-test.
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berin.16–18 This leads to the inhibition of tuberin GTPase
activity against Rheb and an increase in Rheb-GTP that
activates mTOR. Activated mTOR phosphorylates
p70S6K and 4EBP1, and thus enables the translational
machinery and promotes cell growth.13 There was no
increase in the number of A cells cultured for 21 days in
the absence of EGF or the presence of IGF-1, but Akt
phosphorylation was greater than in the A cells grown in
a medium containing EGF.
Hyperphosphorylation of p70S6K and its ribosomal
protein S6 substrate has been observed in cells lacking
tuberin from the Eker rat model of TSC2,19,34 in tumor
cells containing TSC2 mutations,3,33 and in cells lacking
hamartin from a murine model of TSC1,35 thus demon-
strating that the hamartin-tuberin complex negatively reg-
ulates p70S6K. After 21 days of culture in a standard
medium containing EGF, or in a medium deprived of EGF
with or without the addition of IGF-1, phosphorylation of
S6K and its substrate S6 in the A cells were unchanged
which, as recently reported,19,34,36 indicates that the loss
of TSC2 function in mammalian cells leads to constitutive
S6K1 activation and phosphorylation of S6. Preliminary
results suggest that S6K1 is constitutively activated also
in R cells (unpublished data).
Hyperphosphorylation of 4EBP1 reduces its affinity for
eukaryotic initiation factor (eIF)4E and its subsequent
dissociation from eIF4E, and leads to the promotion of
translation.37 The mechanisms of this event are regulated
by the PI 3-kinase pathway and Akt phosphorylation
when induced by insulin,38 and by means of mitogen-
activated protein kinase/extracellular signal-regulated ki-
nase (MEK) when promoted by Erk stimulators.39 The
regulation of 4E-BP1 and eIF4F via MEK/Erk signaling
may be important for the control of translation by mito-
genic signals that do not activate PI 3-kinase/Akt. The
growth of A cells requires EGF supplementation, which
also markedly increased 4EBP1 phosphorylation, which
should lead to dissociation from eIF4E and consequent
translation. The phosphorylation of Erk was not modified
by any culture condition, but mTOR phosphorylation in-
creased in the absence of EGF and IGF-1. It is possible
that A cells grow in the presence of EGF because the
EGF-activated pathway involving Erk modulates 4EBP1
and its translational function. It is known that the Erk
pathway regulates the phosphorylation of multiple 4EBP1
sites to the point that 4EBP1 is released from eIF4E, and
that this activation takes place through mechanisms re-
quiring mTOR (Figure 9).40
It has been reported that exposure to anti-EGF re-
ceptor39,41 and anti-IGF-1 receptor42,43 inhibits the
proliferation, survival, and differentiation of various cul-
tured malignant human cell lines and tumors. Antibod-
ies to EGF and IGF-1 receptors were added to the
culture medium in the presence or absence of EGF,
and both situations led to the progressive loss of A
cells. The activity of A cell EGF receptors is therefore
apparently involved in both proliferation and (perhaps)
survival. The simple omission of EGF from the culture
medium does not cause cell loss, possibly because of
the presence of serum and the autocrine release of
IGF-1 by the A cells themselves. This differentiates
A smooth muscle-like cells from VSMCs: the latter do
not release IGF-1 and their proliferation is stimulated
when it is added to the culture medium, whereas A
cells release a substantial amount of IGF-1 but, even
when added at higher concentrations, it does not pro-
mote A cell proliferation. However, blocking IGF-1R
does cause cell loss, thus suggesting that IGF-1 may
have switched from being a proliferative factor to a
survival factor in A cells. This is confirmed by recent
observations in our laboratory indicating the involve-
ment of IGF-1 in the activation of an A cell anti-
apoptotic pathway (unpublished data).
In conclusion, human LOH smooth muscle-like (A)
and non-LOH epithelial-like (R) TSC2 cells from renal
angiomyolipoma can be isolated, grown in culture, and
indefinitely stored in liquid nitrogen. Unlike that of control
aorta smooth muscle cells, the proliferation of A cells
requires the addition of EGF to the culture medium,
whereas IGF-1 is autocrinally secreted and may play a
role in survival. Incubation with anti-EGFR and anti-IGF1R
causes the loss of 50% of the A cells in 5 days and of
100% in 12 days. These effects of anti-EGFR and anti-
Figure 9. Erk- and PI3K-Akt-dependent cascades regulating mTOR signal-
ing. A: In normal condition, activation of either pathway results in the
phosphorylation of both p90 ribosomal S6 kinase 1 (RSK1) and Akt that, in
turn, are capable of phosphorylating tuberin directly. This inhibits tuberin
function and promotes mTOR-mediated signaling. B: In TSC2 cells, the loss
of tuberin releases the regulation of mTOR and, likely, may lead to the
modification of ERK-RSK1 function with direct/indirect regulation of mTOR.
This may explain the EGF requirement for A cell proliferation.
Table 2. Summary of the Characterization of A and R Cells
Immunocytochemistry Western blotting
-Actin Keratin8/18 HMB45 Hamartin RhoA Tuberin Phosphotuberin Hamartin LOH
A cells         
R cells         
Differences in protein expression between A and R cells. Immunocytochemical staining of A and R cells did not detect S100, vimentin, and
CD68 proteins.
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IGF-1R on A cell survival may offer a new therapeutic
perspective in TSC and LAM.
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